NTUS Natus Medical Incorporated

Natus Medical to Hold 2020 Third Quarter Financial Results Conference Call on October 29th

Natus Medical to Hold 2020 Third Quarter Financial Results Conference Call on October 29th
EN
06/10/2020

Underlying

NTUSNatus Medical Incorporated

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Natus Medical Incorporated

 PRESS RELEASE
Free
NTUS Natus Medical I...

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 ...

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive ...

July 21, 2022 1 EN
 PRESS RELEASE
Free
NTUS Natus Medical I...

Natus Medical Announces First Quarter 2022 Financial Results

Natus Medical Announces First Quarter 2022 Financial Results  Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22     MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022...

May 5, 2022 1 EN
 PRESS RELEASE
Free
NTUS Natus Medical I...

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50...

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash Highlights: •        Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value•        Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announce...

April 18, 2022 1 EN
 PRESS RELEASE
Free
NTUS Natus Medical I...

Natus Medical to Hold 2022 First Quarter Financial Results Conference ...

Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern...

April 1, 2022 1 EN
 PRESS RELEASE
Free
NTUS Natus Medical I...

Natus Medical Announces Fourth Quarter 2021 Financial Results

Natus Medical Announces Fourth Quarter 2021 Financial Results  Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47     PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathw...

February 24, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch